Form 4: ARS Pharmaceuticals CEO Sells 100,000 Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
ARS Pharmaceuticals CEO, Richard E. Lowenthal, sold 100,000 shares of common stock under a pre-arranged 10b5-1 trading plan.
Summary
- Richard E. Lowenthal, CEO of ARS Pharmaceuticals, sold 100,000 shares of common stock on November 19, 2024.
- The sales were executed under a pre-arranged Rule 10b5-1 trading plan established on March 31, 2023.
- 50,000 shares were sold at a weighted average price of $13.9502, with prices ranging from $13.50 to $14.25.
- The other 50,000 shares were sold at a weighted average price of $13.949, with prices ranging from $13.50 to $14.28.
- Following these transactions, Lowenthal directly owns 4,315,313 shares and indirectly owns shares through various trusts.
- The report also details indirect ownership through trusts including the Sarina Tanimoto Charitable Remainder UniTrust, the Lowenthal-Tanimoto Family Trust, and the Richard Lowenthal Charitable Remainder UniTrust.
Sentiment
Score: 5
Explanation: The document is a routine SEC filing for insider stock sales under a pre-arranged plan. It doesn't indicate any positive or negative sentiment, it is a neutral event.
Risks
- Sales by insiders, even under pre-arranged plans, can sometimes be perceived negatively by the market.
Industry Context
This is a routine filing for insider transactions and is common for executives who have pre-arranged trading plans. It does not indicate any specific trend in the pharmaceutical industry.
Comparison to Industry Standards
- Insider sales are a common occurrence in publicly traded companies, especially when executives have pre-arranged trading plans like the 10b5-1 plan used here.
- The sale prices are within a normal range for stock transactions, and the volume of shares sold is not unusual for a CEO's holdings.
- Comparable companies often see similar filings from their executives, and the details of this filing are consistent with standard practices.
Stakeholder Impact
- The stock sale may have a minor impact on the share price, but it is unlikely to have a significant effect on other stakeholders.
Key Dates
| Date | Description |
|---|---|
| 2020-01-07 | Date of the Sarina Tanimoto Charitable Remainder UniTrust and the Richard Lowenthal Charitable Remainder UniTrust. |
| 2023-03-31 | Date the Rule 10b5-1 trading plan was entered into. |
| 2024-11-19 | Date of the stock sales. |
| 2024-11-21 | Date the SEC Form 4 was signed. |
Keywords
ARS Pharmaceuticals, Richard E. Lowenthal, insider trading, stock sale, Rule 10b5-1, SPRY, SEC Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.